Temple University Health System Feb 27 2026 Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new data presented today by Fox Chase Cancer Center researchers. The study also showed that the absence of ctDNA predicted favorable outcomes, regardless of whether the patient's bladder was removed or not. Circulating tumor

Tag-uri: DNA